Acura Pharmaceuticals Inc (ACUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
35
About the Report
About the Report
Summary
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company's proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tampering associated with opioid abuse. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Limitx reduces the level of opioid release when several tablets are swallowed. Aversion irritates the nasal passages upon snorting the product. Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets its products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.
Acura Pharmaceuticals Inc (ACUR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Acura Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 12
KemPharm Enters into Licensing Agreement with Acura Pharma 14
Egalet Enters into Licensing Agreement with Acura Pharma 15
Equity Offering 16
Acura Pharma Raises USD4 Million in Private Placement of Units 16
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 17
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 18
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For USD 3.4 Million 20
Acquisition 21
Acura Pharma Plans to Sell Itself 21
Acura Pharmaceuticals Inc-Key Competitors 22
Acura Pharmaceuticals Inc-Key Employees 23
Acura Pharmaceuticals Inc-Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 14, 2018: Acura Pharmaceuticals announces second quarter 2018 financial results 25
Jun 29, 2018: Acura Pharmaceuticals Reports First Quarter 2018 Financial Results 26
Jun 07, 2018: Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results 27
Nov 13, 2017: Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results 28
Aug 14, 2017: Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results 29
May 12, 2017: Acura Pharmaceuticals Announces First Quarter 2017 Financial Results 30
Mar 31, 2017: Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results 31
Product News 32
09/11/2017: Acura Pharmaceuticals Presenting New LIMITx Clinical Data at the 19th Annual Rodman & Renshaw Conference 32
06/28/2017: Acura Pharmaceuticals Advances LTX-04 and its LIMITx Technology 33
Clinical Trials 34
May 18, 2017: Acura Pharmaceutical Initiates Second Clinical Study on LTX-04 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Figure
List of Figures
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acura Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Acura Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 12
KemPharm Enters into Licensing Agreement with Acura Pharma 14
Egalet Enters into Licensing Agreement with Acura Pharma 15
Acura Pharma Raises USD4 Million in Private Placement of Units 16
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 17
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 18
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For USD 3.4 Million 20
Acura Pharma Plans to Sell Itself 21
Acura Pharmaceuticals Inc, Key Competitors 22
Acura Pharmaceuticals Inc, Key Employees 23
Acura Pharmaceuticals Inc, Subsidiaries 24
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.